The earnings call presented a balanced view with significant advancements in clinical trials, regulatory progress, and sales force readiness. However, these were countered by financial challenges, including increased expenses and a net loss, as well as a delayed PDUFA date impacting timelines for aficamten's approval.

Company Guidance -

Q3 2025

During the Cytokinetics Q2 2025 earnings call, the company provided guidance on several key metrics and milestones for the year. The FDA has extended the PDUFA date for aficamten's NDA to December 26, 2025, with a late-cycle review scheduled for September. The company remains confident in the approvability of aficamten, citing completed GCP inspections with no observations and a productive dialogue with the FDA. In Europe, approval by the EMA is anticipated in the first half of 2026, with Germany targeted for the initial launch. In China, the NDA review for aficamten is on an accelerated pathway, with potential approval expected in the second half of 2025. Commercial readiness activities are underway, including the hiring of a U.S. sales force with over 21 years of industry experience, and preparations for a Q1 2026 U.S. launch. Financially, Cytokinetics reported a net loss of $134.4 million for the second quarter of 2025 and maintained its full-year financial guidance, with GAAP operating expenses projected between $670 million and $710 million. The company has also secured $75 million from a loan with Royalty Pharma and has access to an additional $100 million if needed.

U.S. Sales Force Recruitment

Cytokinetics received over 8,800 applications for their U.S. sales force and hired an experienced cardiovascular sales team with an average of 14 years in the field, positioning them for a Q1 2026 U.S. launch of aficamten.

Positive Clinical Trial Results

Announced positive top-line results from the MAPLE-HCM trial, showing statistically significant improvement in peak oxygen uptake for aficamten compared to metoprolol, with a favorable safety and tolerability profile.

Regulatory Progress in Europe and China

EMA inspections concluded that the Phase III trial was compliant, with potential approval by EMA in the first half of 2026. In China, aficamten is on an accelerated regulatory pathway with expected approval in the second half of this year.

Financial Stability

Ended Q2 with approximately $1.04 billion in cash, with ongoing financial guidance maintaining GAAP operating expense between $670 million and $710 million for the year.

Cytokinetics (CYTK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CYTK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.57 / -	-1.36	―	―	―
Aug 07, 2025	2025 (Q2)	-1.43 / -1.12	-1.31	14.50% (+0.19)	―
May 06, 2025	2025 (Q1)	-1.37 / -1.36	-1.33	-2.26% (-0.03)	―
Feb 27, 2025	2024 (Q4)	-1.19 / -1.26	-1.38	8.70% (+0.12)	―
Nov 06, 2024	2024 (Q3)	-1.24 / -1.36	-1.35	-0.74% (-0.01)	―
Aug 08, 2024	2024 (Q2)	-1.06 / -1.31	-1.34	2.24% (+0.03)	―
May 08, 2024	2024 (Q1)	-1.14 / -1.33	-1.38	3.62% (+0.05)	―
Feb 27, 2024	2023 (Q4)	-0.96 / -1.38	-1.45	4.83% (+0.07)	―
Nov 02, 2023	2023 (Q3)	-0.74 / -1.35	-1.52	11.18% (+0.17)	―
Aug 03, 2023	2023 (Q2)	-1.14 / -1.34	-0.23	-482.61% (-1.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CYTK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$35.25	$34.11	-3.23%
May 06, 2025	$33.97	$33.04	-2.74%
Feb 27, 2025	$47.45	$46.00	-3.06%
Nov 06, 2024	$55.50	$55.84	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytokinetics (CYTK) report earnings?

Cytokinetics (CYTK) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Cytokinetics (CYTK) earnings time?

Cytokinetics (CYTK) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CYTK EPS forecast?

CYTK EPS forecast for the fiscal quarter 2025 (Q3) is -1.57.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing